Transcranial Magnetic Stimulation (TMS) represents one of modern medicine’s most innovative approaches to treating depression and other neurological conditions. However, the technology’s origins stretch back over two centuries, beginning with groundbreaking discoveries that laid the foundation for our current understanding of bioelectricity and electromagnetic stimulation.
The journey from basic scientific principles to today’s sophisticated TMS devices demonstrates how incremental discoveries across generations of researchers ultimately converge to create transformative medical treatments. Understanding this history provides valuable context for appreciating both the scientific rigor and therapeutic potential of TMS therapy.
The story of TMS begins in 1780 with Luigi Galvani, an Italian physician and physicist whose curiosity about electricity led to a pivotal discovery. During his experiments at the University of Bologna, Galvani observed that electrical sparks could cause the legs of dead frogs to twitch and contract. This seemingly simple observation revealed something profound: biological tissue responds to electrical stimulation.

Galvani’s work established the field of electrophysiology and demonstrated that living organisms possess inherent electrical properties. His experiments proved that electrical current could directly influence biological function, a principle that would become fundamental to understanding how the nervous system operates. Without Galvani’s foundational work, the concept of using electrical or electromagnetic fields to stimulate brain tissue would never have emerged.
The Italian physician’s discoveries sparked intense scientific interest across Europe. Researchers began exploring the relationship between electricity and biological systems, leading to numerous experiments that gradually expanded understanding of how electrical stimulation affects muscle and nerve function.
Nearly a century after Galvani’s initial discoveries, English physicist Michael Faraday made the next crucial breakthrough in 1881. Faraday’s experiments revealed the principles of electromagnetic induction, demonstrating that changing electrical currents through a conductor could generate magnetic fields. More importantly, he discovered that these changing magnetic fields could induce electrical currents in nearby conductors.
Faraday’s law of electromagnetic induction became a cornerstone of modern physics and electrical engineering. His work showed that magnetic fields and electrical currents are intimately connected, with each capable of generating the other under specific conditions. This principle would eventually become the theoretical foundation for TMS technology.

The significance of Faraday’s discovery extended far beyond its immediate applications. By establishing that magnetic fields could induce electrical activity, he inadvertently provided the scientific basis for non-invasive brain stimulation. However, it would take over a century before researchers would successfully apply these principles to human neurology.
Despite having the necessary theoretical framework by the late 1800s, practical application of electromagnetic principles to brain stimulation remained elusive for decades. The challenge lay in developing technology sophisticated enough to generate precisely controlled magnetic pulses and understanding how to target specific brain regions safely and effectively.
Throughout the early and mid-20th century, researchers explored various forms of brain stimulation, including electroconvulsive therapy and direct electrical stimulation. These methods provided valuable insights into how external stimulation could influence brain function, but they also highlighted the need for less invasive approaches.
The development of modern electronics and a deeper understanding of neuroanatomy were necessary prerequisites for creating practical TMS devices. By the 1980s, advances in both areas finally made it possible to translate centuries-old scientific principles into clinically viable technology.
The breakthrough moment arrived in 1985 when Dr. Anthony Barker and his research team at the Royal Hallamshire Hospital in Sheffield, England, successfully created the first transcranial magnetic stimulation device. Barker’s innovation involved positioning a specially designed coil on the scalp above the motor cortex and generating brief, powerful magnetic pulses.

The team’s experiments demonstrated that these magnetic pulses could penetrate the skull and induce electrical activity in brain neurons, producing measurable physical responses such as muscle contractions. This achievement proved that electromagnetic stimulation could directly influence brain function without requiring invasive procedures or physical contact with brain tissue.
Barker’s device represented a fundamental advance in neuroscience research methods. For the first time, scientists could stimulate specific brain regions in conscious, healthy subjects without causing discomfort or requiring surgical intervention. This capability opened entirely new avenues for studying brain function and exploring therapeutic applications.
Following Barker’s initial success, TMS quickly gained attention within the neuroscience community. Researchers around the world began experimenting with different coil designs, stimulation parameters, and target brain regions. These early studies focused primarily on understanding basic brain physiology and mapping cortical functions.
The non-invasive nature of TMS made it an invaluable research tool for investigating how different brain areas contribute to motor function, language processing, visual perception, and other cognitive abilities. Researchers could temporarily disrupt or enhance activity in specific brain regions, allowing them to study causal relationships between brain activity and behavior.
During the late 1980s and early 1990s, scientists also began exploring whether TMS could have therapeutic applications. Early studies suggested that repeated stimulation of certain brain regions might influence mood, cognitive function, and other clinically relevant outcomes.
The transition from research instrument to clinical treatment required extensive investigation into TMS safety, efficacy, and optimal treatment protocols. Researchers needed to determine which brain regions to target, what stimulation parameters to use, and how to standardise treatment delivery across different patients and conditions.
Depression emerged as a particularly promising target for TMS therapy. Studies revealed that the prefrontal cortex, a brain region involved in mood regulation and executive function, showed altered activity patterns in depressed patients. Researchers hypothesized that stimulating this area might help restore normal brain function and alleviate depressive symptoms.
Clinical trials throughout the 1990s and early 2000s provided increasingly compelling evidence for TMS effectiveness in treating depression, particularly in patients who had not responded to traditional medications. These studies also established important safety protocols and identified potential side effects, paving the way for regulatory approval.
The culmination of decades of research occurred in 2008 when the U.S. Food and Drug Administration approved TMS for treating Major Depressive Disorder. This approval represented a significant milestone, marking TMS as the first new depression treatment mechanism approved in over a decade.
FDA approval required comprehensive clinical trials demonstrating both safety and efficacy compared to existing treatments. The approval specifically covered repetitive TMS (rTMS) targeting the left prefrontal cortex for patients with treatment-resistant depression, establishing clear guidelines for clinical use.
Following FDA approval, TMS began transitioning from experimental therapy to standard clinical practice. Training programs for healthcare providers emerged, treatment protocols became standardised, and insurance coverage gradually expanded to include TMS therapy for appropriate patients.
Today’s TMS devices have evolved considerably from Barker’s original prototype. Modern systems feature sophisticated targeting methods, real-time monitoring capabilities, and precise control over stimulation parameters. These advances have improved both treatment efficacy and patient comfort.
Current TMS applications extend beyond depression to include obsessive-compulsive disorder, migraine headaches, and various other neurological and psychiatric conditions. Researchers continue investigating potential applications for anxiety disorders, post-traumatic stress disorder, and neurodevelopmental conditions.
The field continues evolving with new stimulation patterns, improved targeting methods, and combination therapies that integrate TMS with other treatments. These developments promise to expand TMS effectiveness and accessibility for patients seeking alternatives to traditional treatment approaches.
Understanding TMS origins reveals how scientific curiosity and methodical research across multiple centuries ultimately created innovative treatment options for patients struggling with treatment-resistant conditions. For those interested in learning more about current TMS applications and treatment options, comprehensive resources are available to help patients and families make informed decisions about mental health care.
Written by Richard Williams, CEO, Transforming Mind Solutions
October 31, 2025